RECRUITING

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

Talk to us

Conditions

Ketosis Prone Diabetesdiabetic ketoacidosistype 2 diabetes

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.

Official Title

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

Quick Facts

Study Start:2024-11
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06699810

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Provide informed consent
  2. * Have a BMI ≥ 28 kg/m2
  3. * Be of African American ancestry
  4. * Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose \> 250 mg/dl, a venous pH \< 7.30, a serum bicarbonate \< 18 mmol/l, and serum ketones (beta-hydroxy butyrate) \> 1.5 mmol/L.
  1. * Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes
  2. * Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism
  3. * Anemia (hemoglobin \< 12.5 g/dL for men, \<11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies
  4. * Pregnant
  5. * Diagnosis of diabetes \> 90 days before the presentation of DKA
  6. * Unable to give consent

Contacts and Locations

Study Contact

Priyathama Vellanki, MD, MS
CONTACT
(404) 778-1687
priyathama.vellanki@emory.edu

Principal Investigator

Priyathama Vellanki, MD, MS
PRINCIPAL_INVESTIGATOR
Emory University

Study Locations (Sites)

Grady Health System
Atlanta, Georgia, 30303
United States
Emory University Hospital Midtown
Atlanta, Georgia, 30308
United States

Collaborators and Investigators

Sponsor: Emory University

  • Priyathama Vellanki, MD, MS, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11
Study Completion Date2025-12

Study Record Updates

Study Start Date2024-11
Study Completion Date2025-12

Terms related to this study

Keywords Provided by Researchers

  • diabetic ketoacidosis
  • type 2 diabetes

Additional Relevant MeSH Terms

  • Ketosis Prone Diabetes